Lymphoma

AVL-292

Description:

AVL-292 is a selective, orally administered, inhibitor of Bruton’s tyrosine kinase (Btk). The expression of Btk is found on B-lymphocytes and has been implicated in the growth and survival of certain B-cell lymphomas as well as in CLL. This is a Phase Ib, escalating dose study of AVL-292 as a monotherapy in subjects with relapsed and/or refractory B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia, and Waldenstrom’s macroglobulinemia


Type(s) of Cancer: Lymphoma
Study Phase(s): Phase II
Contact: Epp Goodwin at (210) 450-5798

IMGN 529

Description:

IMGN 529 consists of CD37 targeting humanized monoclonal antibody and cytotoxic maytansinoid DM1. In this Phase I study IMGN529 is administered intravenously every 3 weeks to patients with relapsed or refractory Non-Hodgkin’s lymphoma.


Type(s) of Cancer: Lymphoma
Study Phase(s): Phase I
Contact: Epp Goodwin at (210) 450-5798

Roflumilast

Description: Roflumilast is a selective long-acting inhibitor of the enzyme PDE-4 with anti-inflammatory effect. This enzyme is also shown to be overexpressed in refractory tumors. In this Phase O/I study Roflumilast is administered orally alone and in combination with Prednisone to patients with relapsed or refractory B-cell lymphoid malignancies.
Type(s) of Cancer: Lymphoma
Study Phase(s): Phase I
Contact: Epp Goodwin at (210) 450-5798